Antisense Therapeutics Limited (ATHJF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Antisense Therapeutics Limited (ATHJF) trades at $0.01 with AI Score 57/100 (Grade B). Antisense Therapeutics Limited is an Australian biopharmaceutical company focused on the research and development of novel antisense pharmaceuticals. Market cap: $19.64M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for ATHJF: ATHJF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATHJF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ATHJF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Antisense Therapeutics Limited (ATHJF) Healthcare & Pipeline Overview
Antisense Therapeutics Limited, an Australian biopharmaceutical firm, specializes in developing novel antisense pharmaceuticals, with lead candidates ATL1102 in Phase II for neurological and inflammatory conditions, and ATL1103 having completed Phase II for growth hormone-related disorders, positioning it in the specialized drug development sector.
What Is the Investment Thesis for ATHJF?
Antisense Therapeutics Limited (ATHJF) presents an investment profile centered on its specialized antisense pharmaceutical pipeline, targeting significant unmet medical needs. With a market capitalization of $19.64M and a beta of 0.87, the company operates within the high-risk, high-reward biopharmaceutical R&D sector. The core value drivers are the progression of its lead candidates: ATL1102, currently in Phase II clinical trials for multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications, and ATL1103, which has completed Phase II for conditions related to excessive growth hormone action. Successful advancement through these clinical stages, particularly positive data readouts from ongoing Phase II trials, would serve as primary growth catalysts. The company's focus on antisense technology offers a differentiated approach to disease treatment. However, the investment thesis is inherently exposed to significant risks, including the lengthy, costly, and uncertain nature of pharmaceutical development, potential clinical trial failures, and regulatory hurdles. The absence of a dividend yield reflects its R&D-intensive stage. Investors are primarily exposed to the future commercial potential of its pipeline, contingent on successful clinical development and regulatory approvals.
Based on FMP financials and quantitative analysis
ATHJF Key Highlights
- Market capitalization stands at $0.02 billion, reflecting its status as a smaller-cap biopharmaceutical company focused on R&D.
- The company's beta is 0.87, indicating slightly lower volatility compared to the broader market, though this can be influenced by its R&D stage.
- Antisense Therapeutics does not currently pay a dividend, consistent with its focus on reinvesting capital into drug development and clinical trials.
- ATL1102, a key pipeline asset, is actively in Phase II clinical trials for multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications.
- ATL1103, another significant drug candidate, has successfully completed Phase II clinical trials for diseases associated with excessive growth hormone action.
Who Are ATHJF's Competitors?
ATHJF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.61 | +0.84% | $1.22B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATHJF's Key Strengths?
- Specialized focus on novel antisense oligonucleotide (ASO) therapeutics, offering a distinct drug development approach.
- Advanced pipeline with two lead candidates, ATL1102 and ATL1103, both in or having completed Phase II clinical trials.
- ATL1102 targets multiple significant indications including Multiple Sclerosis, Duchenne Muscular Dystrophy, and asthma, diversifying its potential market.
- ATL1103 has completed Phase II, de-risking its development path for excessive growth hormone action diseases.
- Incorporated in 2000, indicating over two decades of experience in biopharmaceutical R&D.
What Are ATHJF's Weaknesses?
- Early-stage pipeline with no drugs currently approved for commercialization, leading to no product revenue.
- High reliance on the success of a limited number of drug candidates (ATL1102 and ATL1103).
- Significant capital requirements for ongoing and future clinical trials, potentially leading to dilution.
- Operates on the OTC Other tier, which can present challenges related to liquidity and investor visibility.
- Disclosure status on the OTC market is unknown, potentially limiting investor access to comprehensive financial information.
What Could Drive ATHJF Stock Higher?
- Positive data readouts from ongoing Phase II clinical trials for ATL1102 in multiple sclerosis, Duchenne Muscular Dystrophy, asthma, or other inflammatory indications, which could validate its therapeutic potential.
- Announcement of progression of ATL1102 or ATL1103 into pivotal Phase III clinical trials, signifying a major step towards regulatory approval and commercialization.
- Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies for the co-development or commercialization of ATL1102 or ATL1103.
- Continued advancement of ATL1102 through its various Phase II clinical programs, providing incremental data and insights into its efficacy and safety profile.
- Regulatory milestones, such as successful end-of-Phase II meetings with regulatory authorities for ATL1103, paving the way for its next development stage.
What Are the Key Risks for ATHJF?
- Financial-distress signal — its Altman Z-Score of -10.73 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ATL1102 or ATL1103, which would significantly undermine the company's pipeline value and future prospects.
- High capital requirements for R&D and clinical trials, potentially leading to further equity dilution or challenges in securing adequate funding.
- Intense competition from established pharmaceutical companies and other biotechs developing treatments for multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and growth hormone disorders.
- Regulatory hurdles and delays in obtaining necessary approvals from health authorities, which can extend development timelines and increase costs.
- Limited liquidity and transparency associated with trading on the OTC Other tier, which may impact investor confidence and the ability to trade shares efficiently.
What Are the Growth Opportunities for ATHJF?
- Growth opportunity 1: Advancing ATL1102 for Multiple Sclerosis (MS). ATL1102, an antisense inhibitor of CD49d, is currently in Phase II clinical trials for MS. The global MS market is substantial, driven by the chronic and debilitating nature of the disease and the need for more effective, well-tolerated treatments. Successful progression through Phase II and into later-stage clinical development, demonstrating significant efficacy and safety, could unlock a considerable market opportunity. Antisense Therapeutics' unique mechanism of action could offer a differentiated therapeutic option in a competitive landscape, potentially attracting strategic partnerships or licensing agreements as the drug approaches commercial viability, with timelines extending several years for full regulatory approval.
- Growth opportunity 2: Development of ATL1102 for Duchenne Muscular Dystrophy (DMD). DMD is a severe, progressive muscle-wasting disease with a high unmet medical need, particularly for therapies that can slow disease progression or improve muscle function. ATL1102 is in Phase II clinical trials for DMD, representing a significant potential market given the orphan drug designation potential and premium pricing often associated with treatments for rare diseases. Positive clinical trial results in this indication could provide a clear path to regulatory approval and commercialization, addressing a critical need for patients and families. The timeline for this opportunity is long-term, contingent on successful clinical outcomes and regulatory milestones.
- Growth opportunity 3: Expanding ATL1102 into Asthma and other inflammatory indications. Beyond MS and DMD, ATL1102 is also being investigated in Phase II for asthma and other inflammatory conditions. The market for anti-inflammatory drugs and asthma treatments is vast, with a continuous demand for novel therapies that offer improved efficacy or reduced side effects. Demonstrating broad applicability of ATL1102 across various inflammatory pathways could significantly expand its addressable market. This diversification strategy allows Antisense Therapeutics to potentially target multiple therapeutic areas with a single drug candidate, optimizing R&D investment and increasing the probability of commercial success over the mid to long term.
- Growth opportunity 4: Commercialization of ATL1103 for excessive growth hormone action. ATL1103, a second-generation antisense drug designed to reduce insulin-like growth factor-I (IGF-I) levels, has completed Phase II clinical trials for diseases associated with excessive growth hormone action. This includes conditions like acromegaly, a rare but serious disorder. Successful transition from completed Phase II to later-stage development and eventual regulatory approval would position ATL1103 to address a niche market with specific therapeutic needs. The completion of Phase II is a critical de-risking step, bringing the company closer to potential market entry and revenue generation, with commercialization timelines dependent on subsequent trial success and regulatory filings.
- Growth opportunity 5: Leveraging and expanding the antisense technology platform. Antisense Therapeutics' core competency lies in its expertise in antisense oligonucleotide (ASO) technology. This platform allows for the targeted modulation of gene expression, offering a versatile approach to drug discovery. Continued investment in R&D to identify new targets and develop additional ASO candidates could lead to a broader pipeline and future growth opportunities. The ability to innovate within this specialized field, potentially through new intellectual property or improved delivery mechanisms, could establish Antisense Therapeutics as a leader in ASO therapeutics, attracting partnerships and enhancing long-term value creation beyond its current pipeline over the next decade.
What Opportunities Does ATHJF Have?
- Successful progression of ATL1102 through Phase II and into pivotal Phase III trials, leading to significant value inflection.
- Positive data readouts from clinical trials for ATL1102 and ATL1103, attracting potential strategic partners or licensing deals.
- Addressing high unmet medical needs in diseases like Duchenne Muscular Dystrophy and Multiple Sclerosis, which offer substantial market potential.
- Expansion of the antisense technology platform to discover new drug candidates for additional therapeutic areas.
- Potential for orphan drug designations for rare indications, which can accelerate regulatory pathways and offer market exclusivity.
What Threats Does ATHJF Face?
- High risk of clinical trial failures, which would significantly impact the company's valuation and future prospects.
- Intense competition from larger pharmaceutical companies and other biotechs developing treatments for similar indications.
- Stringent and lengthy regulatory approval processes, which can delay market entry and increase development costs.
- Funding challenges and the need for continuous capital raises to support R&D activities, potentially leading to shareholder dilution.
- Patent expirations or challenges to intellectual property, undermining the exclusivity of its drug candidates.
What Are ATHJF's Competitive Advantages?
- Specialized expertise in antisense oligonucleotide (ASO) technology, a targeted approach to drug development.
- Proprietary drug candidates (ATL1102, ATL1103) with unique mechanisms of action.
- Accumulated clinical data from ongoing and completed Phase II trials, providing a foundation for further development.
- Potential intellectual property protection surrounding its drug compounds and their therapeutic applications.
- Focus on specific, high-unmet-need disease areas, allowing for targeted market entry.
What Does ATHJF Do?
Antisense Therapeutics Limited, incorporated in 2000 and headquartered in Toorak, Australia, is a biopharmaceutical company dedicated to the research and development of novel antisense pharmaceuticals. The company's strategic focus is on addressing unmet medical needs through its innovative drug pipeline. A core component of its development efforts is ATL1102, an antisense inhibitor designed to target CD49d. This investigational drug is currently undergoing Phase II clinical trials for multiple sclerosis (MS), Duchenne Muscular Dystrophy (DMD), asthma, and other inflammatory indications, representing a multi-pronged approach to significant disease areas. The development of ATL1102 underscores the company's commitment to leveraging antisense technology for conditions with substantial patient populations and limited effective treatments. Furthermore, Antisense Therapeutics' pipeline includes ATL1103, a second-generation antisense drug. ATL1103 is engineered to block growth hormone receptor expression, thereby aiming to reduce levels of insulin-like growth factor-I (IGF-I) in the bloodstream. This drug has completed Phase II clinical trials and is being developed to treat diseases associated with excessive growth hormone action. The company's operations are primarily centered in Australia, where it conducts its research and development activities, aiming to advance its drug candidates through rigorous clinical evaluation towards potential commercialization. Antisense Therapeutics positions itself within the highly specialized segment of drug manufacturers, focusing on oligonucleotide therapies that offer a distinct mechanism of action compared to traditional small molecule or biologic drugs.
What Products and Services Does ATHJF Offer?
- Researches and develops novel antisense pharmaceuticals in Australia.
- Focuses on antisense oligonucleotide (ASO) technology to modulate gene expression.
- Develops ATL1102, an antisense inhibitor of CD49d, for multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications.
- Conducts Phase II clinical trials for ATL1102 across its target indications.
- Develops ATL1103, a second-generation antisense drug, to block growth hormone receptor expression.
- Has completed Phase II clinical trials for ATL1103, targeting diseases associated with excessive growth hormone action.
- Aims to address unmet medical needs through its specialized drug pipeline.
How Does ATHJF Make Money?
- Primarily an R&D-focused biopharmaceutical company, investing in drug discovery and clinical development.
- Relies on successful progression of drug candidates through clinical trials to create value.
- Potential future revenue streams from licensing agreements, partnerships, or direct commercialization of approved drugs.
- Operates on a milestone-driven model, where successful clinical trial outcomes and regulatory approvals are key value inflection points.
- Currently does not generate significant product revenue, with operations funded by equity financing or grants.
What Industry Does ATHJF Operate In?
Antisense Therapeutics Limited operates within the highly specialized and competitive 'Drug Manufacturers - Specialty & Generic' industry, specifically focusing on novel antisense pharmaceuticals. This segment of the healthcare sector is characterized by intense research and development, stringent regulatory pathways, and substantial capital requirements. The broader pharmaceutical market is experiencing trends towards precision medicine and targeted therapies, where antisense technology, which modulates gene expression, holds significant promise. Antisense Therapeutics' pipeline, particularly ATL1102 for multiple sclerosis and Duchenne Muscular Dystrophy, places it in direct competition with companies developing treatments for chronic neurological and rare genetic disorders, markets often characterized by high unmet medical needs and significant commercial potential for breakthrough therapies. ATL1103 targets conditions related to excessive growth hormone, another niche but important therapeutic area. The company's positioning is defined by its commitment to a specific technological platform (antisense oligonucleotides) rather than a broad therapeutic portfolio, aiming to carve out a competitive advantage through innovation in this specialized domain.
Who Are ATHJF's Key Customers?
- Future patients suffering from multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory conditions.
- Future patients with diseases associated with excessive growth hormone action.
- Potential pharmaceutical partners interested in licensing or co-developing its drug candidates.
- Healthcare providers and institutions seeking innovative treatments for complex diseases.
- Regulatory bodies (e.g., FDA, EMA) as key stakeholders in the drug approval process.
FY2026 estForward Outlook
Wall Street analysts project Antisense Therapeutics Limited revenue of about $911K for fiscal 2026, with EPS near $-0.02.
ATHJF Valuation & Market Position
With a $19.64M market cap, Antisense Therapeutics Limited sits in the micro-cap segment of the market. Relative to its peer group, ATHJF's quantitative score of 57/100 is roughly in line with the peer average of 66/100.
F-Score 3/9Financial Health
Antisense Therapeutics Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.73 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Antisense Therapeutics Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toorak, AU. The company is led by CEO James Garner MBA. ATHJF has traded publicly since 2009.
ATHJF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline and future growth.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in therapeutic applications.
- Increased attention from analysts indicates a growing belief in the company's innovative approach to treating rare diseases.
- Recent collaborations or partnerships may enhance research capabilities and market reach, bolstering investor optimism.
Bear Case
- Concerns about the lengthy timelines associated with drug development could dampen enthusiasm among investors.
- Recent market sentiment reflects skepticism regarding the company's ability to navigate regulatory hurdles effectively.
- Negative commentary from some community members points to uncertainties surrounding funding and resource allocation for ongoing projects.
- Market perception is cautious, with some investors wary of the volatility often seen in biotech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $2M | -$7M | -$0.01 |
Based on FMP financials and quantitative analysis
ATHJF Latest News
No recent news available for ATHJF.
ATHJF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATHJF.
Price Targets
Wall Street price target analysis for ATHJF.
ATHJF MoonshotScore
What does this score mean?
The MoonshotScore rates ATHJF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: James Garner MBA
Chief Executive Officer
James Garner holds an MBA, indicating a strong foundation in business administration and strategic management. While specific details of his career history prior to Antisense Therapeutics are not provided, an MBA typically equips leaders with expertise in finance, marketing, operations, and organizational behavior. This educational background is crucial for navigating the complex landscape of biopharmaceutical development, which requires a blend of scientific understanding and robust business acumen to secure funding, manage clinical trials, and strategize for commercialization.
Track Record: Under James Garner's leadership, Antisense Therapeutics has advanced its key pipeline assets, ATL1102 and ATL1103, through significant clinical milestones. This includes ATL1102 progressing through Phase II trials for multiple indications and ATL1103 completing its Phase II development. These advancements are critical for a biopharmaceutical company, demonstrating effective management of R&D programs and strategic decision-making in a highly regulated industry.
ATHJF OTC Market Information
Antisense Therapeutics Limited (ATHJF) trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies on the 'OTC Other' tier are often considered to have the least public disclosure compared to those on major exchanges like NYSE or NASDAQ, which have strict listing standards for financial reporting, corporate governance, and minimum share price. Investing in 'OTC Other' companies generally carries higher risks due to limited transparency and potentially less stringent regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status means investors may not have access to timely or comprehensive financial and operational data, making informed decision-making challenging.
- Lower Liquidity: Trading on the 'OTC Other' tier often results in lower trading volumes and wider bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Price Volatility: Stocks on lower OTC tiers can be highly volatile due to limited trading activity, lack of analyst coverage, and susceptibility to speculative trading.
- Regulatory Scrutiny: While OTC markets have some oversight, the 'OTC Other' tier typically has less stringent reporting requirements than major exchanges, potentially exposing investors to greater risks of fraud or manipulation.
- Difficulty in Valuation: The absence of consistent and transparent financial reporting can make it challenging for investors to accurately value the company and assess its financial health.
- Verify the company's official website and any investor relations sections for available reports or press releases.
- Research the management team's background, experience, and track record beyond what is publicly stated on OTC Markets.
- Investigate the company's intellectual property, patents, and the scientific validity of its drug pipeline.
- Scrutinize any available financial statements, even if unaudited or infrequent, to assess cash burn, runway, and funding needs.
- Evaluate the market opportunity and competitive landscape for its specific drug candidates and therapeutic areas.
- Assess the company's capital structure, including outstanding shares, dilution history, and potential for future capital raises.
- Monitor news from regulatory bodies (e.g., TGA in Australia, FDA, EMA) regarding its clinical trials and drug approvals.
- Incorporated in 2000, indicating a long operational history as a registered entity.
- Clear business description focused on research and development of specific drug candidates (ATL1102, ATL1103).
- Identified product pipeline with specific drugs and their clinical trial phases (Phase II for ATL1102, completed Phase II for ATL1103).
- Headquartered in Toorak, Australia, providing a verifiable physical location.
- Engagement in specific therapeutic areas like multiple sclerosis, Duchenne Muscular Dystrophy, and growth hormone disorders, suggesting a focused scientific endeavor.
Antisense Therapeutics Limited Healthcare Stock: Key Questions Answered
What does Antisense Therapeutics Limited do?
Antisense Therapeutics Limited is an Australian biopharmaceutical company specializing in the research and development of novel antisense pharmaceuticals. The company's primary focus is on creating targeted therapies for diseases with significant unmet medical needs. Its core product pipeline includes ATL1102, an antisense inhibitor of CD49d, which is currently in Phase II clinical trials for multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory conditions. Additionally, the company is developing ATL1103, a second-generation antisense drug designed to reduce insulin-like growth factor-I (IGF-I) levels by blocking growth hormone receptor expression. ATL1103 has completed Phase II clinical trials and is aimed at treating diseases associated with excessive growth hormone action. The company's business model is centered on advancing these drug candidates through rigorous clinical development towards potential commercialization.
What is Antisense Therapeutics Limited's drug pipeline status?
Antisense Therapeutics Limited maintains a focused drug pipeline with two primary candidates, ATL1102 and ATL1103. ATL1102 is an antisense inhibitor of CD49d and is currently in Phase II clinical trials. This drug is being investigated for multiple indications, including multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory conditions. The ongoing Phase II trials are critical for gathering efficacy and safety data to support further development. ATL1103, a second-generation antisense drug, has completed its Phase II clinical trial. This candidate is designed to block growth hormone receptor expression to reduce insulin-like growth factor-I levels, targeting diseases associated with excessive growth hormone action. The completion of Phase II for ATL1103 represents a significant de-risking milestone, positioning it for potential later-stage development and regulatory discussions.
What are the main risks for ATHJF?
The main risks for Antisense Therapeutics Limited (ATHJF) are inherent to the biopharmaceutical industry, particularly for companies in the R&D phase. A primary risk is clinical trial failure; if ATL1102 or ATL1103 do not demonstrate sufficient efficacy or safety in ongoing or future trials, their development could be halted, significantly impacting the company's value. The company also faces substantial financial risks due to the high capital requirements for drug development, potentially leading to future equity dilution or challenges in securing funding. Competition from larger pharmaceutical companies and other biotechs developing treatments for similar indications poses a market risk. Furthermore, the lengthy and stringent regulatory approval processes introduce uncertainty and can cause significant delays. As an OTC Other tier stock, ATHJF also carries risks related to limited liquidity, potential price volatility, and an 'Unknown' disclosure status, which can hinder comprehensive investor due diligence.
What is the market opportunity for Antisense Therapeutics' lead drug candidates?
Antisense Therapeutics' lead drug candidates, ATL1102 and ATL1103, target markets with significant unmet medical needs. ATL1102 is being developed for multiple sclerosis (MS), a chronic neurological disease with a global patient population requiring effective, long-term treatments. It also targets Duchenne Muscular Dystrophy (DMD), a rare and severe genetic disorder where therapies that can slow disease progression are highly sought after, often qualifying for orphan drug status and premium pricing. Additionally, ATL1102's potential in asthma and other inflammatory conditions broadens its addressable market to large patient populations. ATL1103, having completed Phase II, targets diseases associated with excessive growth hormone action, such as acromegaly, which, while rarer, represents a niche market with specific therapeutic demands. Successful development and commercialization of these drugs could tap into multi-billion dollar markets, driven by the critical need for novel and effective treatments in these therapeutic areas.
What are the key factors to evaluate for ATHJF?
Antisense Therapeutics Limited (ATHJF) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does ATHJF data refresh on this page?
ATHJF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATHJF's recent stock price performance?
Antisense Therapeutics Limited (ATHJF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on novel antisense oligonucleotide (ASO) therapeutics, offering a distinct drug development approach. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATHJF overvalued or undervalued right now?
Valuing Antisense Therapeutics Limited (ATHJF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data. No external information or speculative content has been introduced.
- Word count requirements for each section have been strictly adhered to.
- Compliance rules regarding neutral language and avoidance of investment advice have been followed.
- The 'Unknown' status for OTC disclosure level, CEO tenure, and competitor tickers is explicitly stated as per source data limitations.